

**Table 1: Overview of studies included in the RP2 research portfolio.** The portfolio comprises 24 studies conducted across two major sub-Saharan African sites (Abidjan, Côte d’Ivoire and Johannesburg, South Africa) spanning multiple research domains including HIV treatment, prevention, mother-to-child transmission (MTCT), and COVID-19 response. Study types include randomized controlled trials, observational cohorts, community-based studies, and collaborative network trials. Sample sizes range from 78 to 2,930 participants, with a total enrollment of 20,074 individuals across all studies.

Study ID	Study Name	City	Sample Size	Study Type	Period
<i>Abidjan, Côte d’Ivoire</i>					
PACCLTemprano	ANRS 12136 Temprano Trial	Abidjan	2,056	Clinical Trial	2008–15
PACCLStatis	ANRS 12289 STATIS Trial	Abidjan	1,571	Clinical Trial	2013–17
PACCLPrimo.CI	Primo-CI Cohort	Abidjan	1,534	Cohort	2004–10
PACCLDitrame-Plus	Ditrame-Plus MTCT	Abidjan	1,200	MTCT	2001–05
PACCLMTCT-Plus	MTCT-Plus Program	Abidjan	890	MTCT	2003–08
PACCLVoltart	ANRS 12186 VOLTART	Abidjan	738	Clinical Trial	2012–16
PACCLTrivacan	Trivacan Study	Abidjan	672	Clinical Trial	2009–12
PACCLVirage	VIRAGE Cohort	Abidjan	501	Cohort	2010–15
<i>Johannesburg, South Africa</i>					
JHB_Aurum.009	Thol’impilo HIV Linkage	J’burg	2,930	Community	2013–17
JHB_VIDA.007	ChAdOx1 COVID Vaccine	J’burg	2,129	COVID-19	2020
JHB_WRHI.001	WRHI001 Stavudine vs Tenofovir	J’burg	1,072	Clinical Trial	Multi-year
JHB_EZIN.002	ADVANCE HIV Trial	J’burg	1,053	Clinical Trial	2017–18
JHB_DPHRU.053	MASC Study	J’burg	1,013	Cohort	2017
JHB_ACTG.021	ACTG 5199 Neurological Study	J’burg	671	ACTG	2006–10
JHB_VIDA.008	COVID Healthcare Worker Study	J’burg	557	COVID-19	Apr–Sep 2020
JHB_JHSPH.005	TB Prevention Trial	J’burg	524	Academic	Multi-year
JHB_SCHARP.006	HPTN 082 PrEP Young Women	J’burg	451	Prevention	2016–18
JHB_SCHARP.004	HPTN 075 MSM Prevention	J’burg	401	Prevention	2015–17
JHB_WRHI.003	WRHI003 Darunavir vs Lopinavir	J’burg	305	Clinical Trial	2016–17
JHB_DPHRU.013	Birth to Twenty Plus Cohort	J’burg	247	Cohort	2011–13
JHB_EZIN.025	EZIN025 COVID Treatment	J’burg	192	COVID-19	2020
JHB_ACTG.015	ACTG 5208 Nevirapine Trial	J’burg	177	ACTG	2005–08
JHB_ACTG.016	ACTG 5221 HIV/TB Coinfection	J’burg	78	ACTG	2007–08

**Study types:** ACTG, AIDS Clinical Trials Group; COVID-19, coronavirus disease 2019 studies; MTCT, mother-to-child transmission studies. Multi-year indicates studies spanning multiple years with specific dates not available. The RP2 portfolio represents collaborative research across francophone and anglophone sub-Saharan Africa, encompassing diverse study designs and research questions in HIV/AIDS and infectious disease research. Total participant enrollment across all studies:  $n = 20,074$ .

**Table 2: Summary characteristics of the RP2 study portfolio.**

<b>Characteristic</b>	<b>Value</b>
Total number of studies	24
Total participants enrolled	20,074
Study sites	2
Abidjan, Côte d'Ivoire	8 studies
Johannesburg, South Africa	16 studies
<b>Study types</b>	
Clinical trials	10
Cohort studies	4
COVID-19 studies	3
ACTG trials	3
Prevention studies	2
MTCT studies	2
<b>Sample size distribution</b>	
Median (IQR)	738 (305–1,072)
Range	78–2,930
Studies with >1,000 participants	9